Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer

Affiliations

¹ Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy paolo.giorgirossi@ausl.re.it.
² University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ McMaster University, Hamilton, ON, Canada.

Comment

Paolo Giorgi Rossi et al. N Engl J Med. 2019.

. 2019 Sep 26;381(13):1289-1290.

doi: 10.1056/NEJMc1909693.

¹ Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy paolo.giorgirossi@ausl.re.it.
² University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ McMaster University, Hamilton, ON, Canada.

No abstract available

Comment in

Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer. Reply.
Sparano JA. Sparano JA. N Engl J Med. 2019 Sep 26;381(13):1290-1291. doi: 10.1056/NEJMc1909693. N Engl J Med. 2019. PMID: 31553846 No abstract available.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Sparano JA, et al. N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3. N Engl J Med. 2019. PMID: 31157962 Free PMC article. Clinical Trial.